The Martins lab at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology is looking for a Postdoctoral Associate. Our research program is focused on developing a "one-shot" functional cure for HIV/AIDS. To that end, we are leveraging the latest advances in gene therapy to engineer long-lived host cells to continuously produce HIV-1 IgG therapeutics in vivo at levels sufficient to prevent viral replication in the absence of antiretroviral therapy (ART). Using nonhuman primates as a preclinical model of HIV/AIDS, we have shown that a single dose of adeno-associated virus (AAV) vectors at birth can result in stable expression of a HIV-1 broadly neutralizing antibody (bNAb) in plasma for years without redosing. The systemic HIV-1 immunity achieved by this strategy could block acquisition of simian-HIV infection (SHIV) in mucosal challenge models that mimic HIV transmission through breastfeeding and sexual intercourse. Additionally, ongoing studies in our group show that AAV-vectored delivery of HIV-1 IgG biologics can also prevent virus rebound in SHIV-infected infant and adult rhesus macaques following ART interruption. Despite the promise of these results, AAV-expressed bNAbs often induce host immune responses that restrict bNAb expression and lead to treatment failure. Although these anti-drug antibody (ADA) responses are rarely observed in newborn macaques, a large fraction of AAV/bNAb-treated adult monkeys (and humans too!) develop immune responses that interfere with the half-life or biological activity of the delivered molecules. Thus, a main focus of our lab is to understand why gene therapy with AAV/bNAb vectors induces ADAs in some animals, but not in others, in hopes devising strategies for suppressing these unwanted host immune responses.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Industry
Educational Services
Education Level
Ph.D. or professional degree
Number of Employees
5,001-10,000 employees